TC
AGIO icon

TFS Capital’s Agios Pharmaceuticals AGIO Stock Holding History

TFS Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-7,963
Closed -$312K – 1104
2014
Q1 		$312K Buy
+7,963
New +$266K 0.02% 994
2013
Q4 		– Sell
-18,972
Closed -$530K – 1458
2013
Q3 		$530K Buy
+18,972
New +$524K 0.02% 841

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TRV
Third Rock Ventures Boston, Massachusetts $1.07B AUM 170.23% 1-Year Est. Return
FV2GP
Flagship Ventures 2007 General Partner Cambridge, Massachusetts $107M AUM
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

TFS Capital's AGIO Position: Q2 2014 in Review

TFS Capital sold out of Agios Pharmaceuticals (AGIO) in Q2 2014, closing a stake of 7,963 shares — an estimated $312K sold.

TFS Capital first reported a position in AGIO in Q3 2013 and held it in 2 quarters. The position peaked at $530K in Q3 2013. 99 funds tracked by Wall St. Rank hold AGIO as of Q2 2014.

  • TFS Capital reported no remaining Agios Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • TFS Capital sold 7,963 Agios Pharmaceuticals shares in Q2 2014, an estimated $312K.
  • TFS Capital first reported a position in Agios Pharmaceuticals in Q3 2013 and held it in 2 quarters.
  • TFS Capital's Agios Pharmaceuticals position peaked at $530K in Q3 2013.
  • 99 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2014.

Based on TFS Capital's 13F filing for Q2 2014, filed 21 Jul 2014.